Celestia Diagnostics, founded in Fort Worth, Texas, is a healthcare company dedicated to developing innovative diagnostic tests for infection-associated chronic conditions. Their core mission is to bridge the gap in medical diagnostics by providing accurate and efficient methods for identifying and managing these conditions. One of their primary projects is the development of a blood test for diagnosing Long COVID, leveraging amyloid microthrombi and platelet pathologies to offer a reliable diagnostic tool for this emerging health issue.

The company has garnered attention for its pioneering approach to addressing the diagnostic challenges of Long COVID, a condition affecting millions of Americans. While specific notable affiliated people and investors are not detailed, Celestia Diagnostics' impact is evident in its commitment to enhancing diagnostic accuracy and treatment strategies for chronic conditions linked to infections. Their work holds significant potential for improving patient outcomes and advancing medical research in the field of chronic infectious diseases.